Export financials
Epizyme (EPZM)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Epizyme Financial Statements 2021-2010 | EPZM
Annual Financial Statements Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
126 M | 1.11 B | 1.88 B | 734 M | 993 M | 600 M | 362 M | 632 M | 518 M | - | - | - |
Shares |
103 M | 101 M | 89.9 M | 71.9 M | 61.5 M | 57.1 M | 39.8 M | 33 M | 17 M | 1.64 M | 1.43 M | - |
Historical Prices |
1.23 | 10.9 | 20.9 | 10.2 | 16.1 | 10.5 | 9.09 | 19.1 | 30.4 | - | - | - |
Net Income |
-251 M | -232 M | -170 M | -124 M | -134 M | -110 M | -132 M | -55 M | -3.48 M | -702 K | -21 M | - |
Revenue |
37.4 M | 15.8 M | 23.8 M | 21.7 M | 10 M | 8.01 M | 2.56 M | 41.4 M | 68.5 M | 45.2 M | 6.94 M | - |
Cost of Revenue |
10.5 M | 5.07 M | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | 10.7 M | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-238 M | -225 M | -177 M | -128 M | -137 M | -112 M | -133 M | -55 M | -3.13 M | -768 K | -21 M | - |
Interest Expense |
-22.4 M | -3.97 M | 1.15 M | -25 K | 32 K | 83 K | 79 K | 59 K | -81 K | -78 K | -23 K | - |
EBITDA |
-233 M | -221 M | -176 M | -127 M | -135 M | -110 M | -131 M | -54.3 M | -2.42 M | 79 K | -20.5 M | - |
Operating Expenses |
- | 236 M | 201 M | 150 M | 147 M | 120 M | 135 M | 96.5 M | 71.6 M | - | - | - |
General and Administrative Expenses |
134 M | 125 M | 23.5 M | 12.2 M | 37.2 M | 28.4 M | 23.9 M | 20.9 M | 14 M | 7.51 M | 5 M | - |
All numbers in USD currency
Quarterly Income Statement Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | - | 167 K | 144 K | 106 M | 103 M | 102 M | 102 M | 102 M | 102 M | 101 M | 99.6 M | 95.1 M | 91 M | 90.9 M | 82.4 M | 79 M | 69.5 M | 69.5 M | 69.4 M | 69.3 M | 59.9 M | 58.4 M | 58.2 M | 58 M | 58 M | 57.4 M | 55.1 M | 41.7 M | 41.5 M | 41.1 M | 35 M | 34.3 M | 33.7 M | 33.2 M | 31 M | 28.4 M | 28.4 M | 9.15 M | 1.79 M | 1.67 M | 1.65 M | 1.64 M | 1.62 M | - | - | - | - |
Net Income |
- | - | -35.7 M | -55.5 M | - | -65.8 M | -64.4 M | -70.3 M | -66.2 M | -56.1 M | -58.5 M | -50.9 M | -56.4 M | -36.1 M | -48.5 M | -29.3 M | -22.9 M | -37.5 M | -29.1 M | -34.1 M | -36.2 M | -37.6 M | -28 M | -32.5 M | -35 M | -24.3 M | -28 M | -22.9 M | -22.2 M | -23.1 M | -25.8 M | -61.3 M | -15 M | -19.7 M | -13.4 M | -6.88 M | 15.9 M | -9.7 M | -2.21 M | -7.5 M | -4.54 M | 4.45 M | 4.86 M | -5.47 M | - | - | - | - |
Revenue |
- | - | 27.5 M | 8.7 M | - | 5.2 M | 13 M | 7.63 M | 8.38 M | 3.57 M | 2.47 M | 1.35 M | 4.29 M | 5.72 M | 5.9 M | 7.89 M | 9.7 M | 12 M | 12 M | - | - | 10 M | 10 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | 5.17 M | 2.64 M | - | 2 M | 2.49 M | 2.85 M | 1.82 M | 1.61 M | 1.02 M | 614 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
- | - | -29.8 M | -50.9 M | - | -64.1 M | -58.2 M | -64.3 M | -62.1 M | -54.4 M | -57.6 M | -51.4 M | -57.5 M | -38 M | -50.7 M | -31 M | -24.3 M | -38.6 M | -30.3 M | -35 M | -37.4 M | -38.1 M | -28.5 M | -33 M | -35.5 M | -24.8 M | -28.4 M | -23.1 M | -22.3 M | -23.1 M | -25.8 M | -61.4 M | -15.1 M | -19.7 M | -13.3 M | -6.91 M | 16.3 M | -9.73 M | -2.18 M | -7.48 M | -4.54 M | 4.44 M | 4.8 M | -5.48 M | - | - | - | - |
Interest Expense |
- | - | -5.39 M | -5.48 M | - | -5.64 M | -5.58 M | -5.48 M | -3.97 M | -1.72 M | -885 K | -48 K | 1.15 M | -15 K | -13 K | -6 K | - | -6 K | -11 K | 18 K | - | -32 K | 10 K | 4 K | - | 21 K | - | - | - | - | - | 20 K | - | 17 K | 12 K | 12 K | - | 3 K | -50 K | -39 K | - | -39 K | - | - | - | - | - | - |
EBITDA |
- | - | -27.2 M | -49.6 M | - | -60.2 M | -55.6 M | -63.1 M | -62.1 M | -51.7 M | -56.2 M | -50.8 M | -57.5 M | -37.3 M | -50.3 M | -30.8 M | -24.3 M | -37.8 M | -29.7 M | -34.6 M | -37.4 M | -36.8 M | -27.6 M | -32.6 M | -35.5 M | -23.6 M | -27.6 M | -22.7 M | -22.3 M | -22 M | -25.1 M | -61.1 M | -15.1 M | -19.2 M | -12.9 M | -6.74 M | 16.3 M | -9.19 M | -1.81 M | -7.3 M | -4.54 M | 4.88 M | 5.1 M | -5.48 M | - | - | - | - |
General and Administrative Expenses |
- | - | 24.1 M | 27.2 M | - | 32.8 M | 33.9 M | 36.4 M | 35 M | 30.6 M | 32.7 M | 26.9 M | 23.5 M | 17.1 M | 15.7 M | 12 M | 12.2 M | 11.5 M | 10.9 M | 9.36 M | 8.43 M | 9.31 M | 11.2 M | 8.27 M | 7.58 M | 7.52 M | 7.42 M | 5.85 M | 6.02 M | 6.68 M | 5.97 M | 5.24 M | 4.94 M | 5.67 M | 5.31 M | 4.96 M | 4.38 M | 3.59 M | 3.08 M | 3 M | 2.33 M | 1.63 M | 1.64 M | 1.91 M | - | - | - | - |
All numbers in USD currency
Main types of financial statements Epizyme EPZMFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Epizyme plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Regeneron Pharmaceuticals
REGN
|
$ 726.47 | 0.05 % | $ 76 B | ||
|
Replimune Group
REPL
|
$ 13.15 | 0.61 % | $ 1.22 B | ||
|
Rafael Holdings
RFL
|
$ 1.47 | 0.65 % | $ 43.3 M | ||
|
REGENXBIO
RGNX
|
$ 7.76 | 4.44 % | $ 400 M | ||
|
Rigel Pharmaceuticals
RIGL
|
$ 47.79 | 1.36 % | $ 860 M | ||
|
Relay Therapeutics
RLAY
|
$ 19.39 | 2.27 % | $ 3.33 B | ||
|
Avidity Biosciences
RNA
|
$ 7.97 | 1.66 % | $ 1.1 B | ||
|
Royalty Pharma plc
RPRX
|
$ 56.66 | 0.36 % | $ 24.4 B | ||
|
Revolution Medicines
RVMD
|
$ 207.68 | 0.5 % | $ 39.5 B | ||
|
Rhythm Pharmaceuticals
RYTM
|
$ 92.45 | 0.24 % | $ 6.01 B | ||
|
Rezolute
RZLT
|
$ 4.33 | 7.98 % | $ 450 M | ||
|
Sana Biotechnology
SANA
|
$ 2.88 | 1.21 % | $ 729 M | ||
|
Seer
SEER
|
$ 2.33 | 3.56 % | $ 129 M | ||
|
SIGA Technologies
SIGA
|
$ 3.48 | 2.96 % | $ 249 M | ||
|
Sol-Gel Technologies Ltd.
SLGL
|
$ 78.95 | 9.65 % | $ 220 M | ||
|
Silence Therapeutics plc
SLN
|
$ 10.14 | 0.78 % | $ 1.44 B | ||
|
SELLAS Life Sciences Group
SLS
|
$ 11.63 | 3.62 % | $ 1.27 B | ||
|
Summit Therapeutics
SMMT
|
$ 17.27 | 3.07 % | $ 12.9 B | ||
|
Syndax Pharmaceuticals
SNDX
|
$ 17.83 | 1.31 % | $ 1.54 B | ||
|
Soligenix
SNGX
|
$ 0.36 | 0.6 % | $ 1.87 M | ||
|
Sanofi
SNY
|
$ 39.51 | 1.19 % | $ 48.2 B | ||
|
Spruce Biosciences
SPRB
|
$ 45.42 | 2.1 % | $ 34.8 M | ||
|
Spero Therapeutics
SPRO
|
$ 1.16 | 4.13 % | $ 65 M | ||
|
Sarepta Therapeutics
SRPT
|
$ 17.49 | 0.7 % | $ 1.75 B | ||
|
Scholar Rock Holding Corporation
SRRK
|
$ 43.4 | 1.41 % | $ 4.98 B | ||
|
Stoke Therapeutics
STOK
|
$ 25.32 | 0.8 % | $ 1.5 B | ||
|
Sutro Biopharma
STRO
|
$ 15.13 | 0.23 % | $ 129 M | ||
|
Shattuck Labs
STTK
|
$ 6.5 | 1.04 % | $ 452 M | ||
|
Supernus Pharmaceuticals
SUPN
|
$ 42.76 | 0.9 % | $ 2.41 B | ||
|
Sesen Bio
SESN
|
- | 7.29 % | $ 127 M | ||
|
Savara
SVRA
|
$ 4.78 | 0.1 % | $ 1.06 B | ||
|
China SXT Pharmaceuticals
SXTC
|
$ 2.08 | 1.99 % | $ 1.41 M | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
$ 17.81 | 0.08 % | $ 28.1 B | ||
|
Protara Therapeutics
TARA
|
$ 2.63 | 0.36 % | $ 113 M | ||
|
Tarsus Pharmaceuticals
TARS
|
$ 74.46 | 1.99 % | $ 3.11 B | ||
|
Bio-Techne Corporation
TECH
|
$ 72.58 | 0.25 % | $ 11.3 B | ||
|
Tenax Therapeutics
TENX
|
$ 1.96 | 2.59 % | $ 76.9 M | ||
|
Teva Pharmaceutical Industries Limited
TEVA
|
$ 39.66 | 0.33 % | $ 45.4 B | ||
|
TG Therapeutics
TGTX
|
$ 53.91 | 0.12 % | $ 7.78 B | ||
|
Tonix Pharmaceuticals Holding Corp.
TNXP
|
$ 8.07 | 0.54 % | $ 68.7 M | ||
|
Trevi Therapeutics
TRVI
|
$ 13.72 | 0.99 % | $ 1.85 B | ||
|
Taysha Gene Therapies
TSHA
|
$ 4.49 | 0.11 % | $ 1.44 B | ||
|
UroGen Pharma Ltd.
URGN
|
$ 42.78 | 3.33 % | $ 2.06 B | ||
|
United Therapeutics Corporation
UTHR
|
$ 536.4 | 0.37 % | $ 23.8 B | ||
|
Vericel Corporation
VCEL
|
$ 41.07 | 2.29 % | $ 2.07 B | ||
|
Veracyte
VCYT
|
$ 47.67 | 4.06 % | $ 3.75 B | ||
|
Vir Biotechnology
VIR
|
$ 11.78 | 5.46 % | $ 1.63 B | ||
|
Viking Therapeutics
VKTX
|
$ 29.28 | 0.36 % | $ 3.3 B | ||
|
Vanda Pharmaceuticals
VNDA
|
$ 4.58 | 0.51 % | $ 270 M | ||
|
Verrica Pharmaceuticals
VRCA
|
$ 4.31 | 0.21 % | $ 45.9 M |